Point-of-care blood diagnostics platform developer HemoSonics raised $15 million in a new round of equity financing, according to an SEC filing posted this week.
The Charlottesville, Va.-based company produces the Quanta rapid diagnostic designed to measure treatable aspects of hemostasis in approximately 15 minutes, according to the company’s website. The device measures treatable aspects of coagulation and operates around consumable cartridges, according to the company.
All $15 million in the round came from 1 unnamed investor, according to an SEC filing, with a total of $1.1 million paid in sales commissions.
Proceeds from the round will be used to support general working capital, according to the filing.